<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p62" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_62{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_62{left:341px;bottom:30px;}
#t3_62{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_62{left:377px;bottom:30px;}
#t5_62{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_62{left:540px;bottom:30px;}
#t7_62{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_62{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_62{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_62{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_62{left:285px;bottom:827px;letter-spacing:-0.39px;word-spacing:0.12px;}
#tc_62{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_62{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_62{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_62{left:1107px;bottom:28px;letter-spacing:0.34px;}
#tg_62{left:36px;bottom:232px;}
#th_62{left:46px;bottom:226px;letter-spacing:0.08px;word-spacing:-0.01px;}
#ti_62{left:377px;bottom:226px;letter-spacing:0.12px;}
#tj_62{left:407px;bottom:226px;letter-spacing:0.13px;}
#tk_62{left:481px;bottom:226px;}
#tl_62{left:36px;bottom:215px;}
#tm_62{left:46px;bottom:209px;letter-spacing:0.12px;}
#tn_62{left:45px;bottom:192px;letter-spacing:0.12px;}
#to_62{left:36px;bottom:182px;}
#tp_62{left:46px;bottom:176px;letter-spacing:0.1px;word-spacing:0.02px;}
#tq_62{left:45px;bottom:159px;letter-spacing:0.12px;}
#tr_62{left:45px;bottom:142px;letter-spacing:0.11px;word-spacing:-0.1px;}
#ts_62{left:36px;bottom:131px;}
#tt_62{left:46px;bottom:125px;letter-spacing:0.11px;word-spacing:0.02px;}
#tu_62{left:45px;bottom:108px;letter-spacing:0.12px;}
#tv_62{left:438px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#tw_62{left:765px;bottom:786px;}
#tx_62{left:36px;bottom:748px;letter-spacing:-0.1px;}
#ty_62{left:36px;bottom:728px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#tz_62{left:36px;bottom:709px;letter-spacing:-0.1px;}
#t10_62{left:41px;bottom:690px;}
#t11_62{left:58px;bottom:690px;letter-spacing:-0.09px;}
#t12_62{left:58px;bottom:671px;letter-spacing:-0.09px;}
#t13_62{left:58px;bottom:652px;letter-spacing:-0.09px;}
#t14_62{left:63px;bottom:633px;}
#t15_62{left:76px;bottom:633px;letter-spacing:-0.09px;}
#t16_62{left:77px;bottom:614px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t17_62{left:91px;bottom:595px;letter-spacing:-0.27px;}
#t18_62{left:359px;bottom:602px;letter-spacing:-0.25px;}
#t19_62{left:77px;bottom:576px;letter-spacing:-0.16px;word-spacing:0.01px;}
#t1a_62{left:92px;bottom:557px;}
#t1b_62{left:103px;bottom:557px;letter-spacing:-0.09px;}
#t1c_62{left:103px;bottom:539px;letter-spacing:-0.09px;}
#t1d_62{left:103px;bottom:521px;letter-spacing:-0.1px;}
#t1e_62{left:92px;bottom:502px;}
#t1f_62{left:103px;bottom:502px;letter-spacing:-0.09px;}
#t1g_62{left:77px;bottom:483px;letter-spacing:-0.09px;word-spacing:-0.04px;}
#t1h_62{left:91px;bottom:463px;letter-spacing:-0.08px;}
#t1i_62{left:41px;bottom:444px;}
#t1j_62{left:58px;bottom:444px;letter-spacing:-0.09px;}
#t1k_62{left:63px;bottom:425px;}
#t1l_62{left:76px;bottom:425px;letter-spacing:-0.09px;}
#t1m_62{left:547px;bottom:433px;letter-spacing:-0.12px;}
#t1n_62{left:36px;bottom:393px;letter-spacing:0.34px;word-spacing:-0.18px;}
#t1o_62{left:378px;bottom:401px;}
#t1p_62{left:36px;bottom:374px;letter-spacing:-0.1px;}
#t1q_62{left:41px;bottom:355px;}
#t1r_62{left:58px;bottom:355px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t1s_62{left:58px;bottom:336px;letter-spacing:-0.1px;}
#t1t_62{left:216px;bottom:343px;}
#t1u_62{left:41px;bottom:317px;}
#t1v_62{left:58px;bottom:317px;letter-spacing:-0.09px;}
#t1w_62{left:58px;bottom:298px;letter-spacing:-0.09px;}
#t1x_62{left:219px;bottom:305px;letter-spacing:-0.12px;}
#t1y_62{left:614px;bottom:748px;letter-spacing:-0.24px;}
#t1z_62{left:614px;bottom:728px;letter-spacing:-0.1px;}
#t20_62{left:929px;bottom:736px;}
#t21_62{left:614px;bottom:709px;}
#t22_62{left:624px;bottom:709px;letter-spacing:-0.43px;}
#t23_62{left:614px;bottom:690px;letter-spacing:-0.08px;}
#t24_62{left:620px;bottom:671px;}
#t25_62{left:636px;bottom:671px;letter-spacing:-0.09px;word-spacing:-0.08px;}
#t26_62{left:1150px;bottom:679px;}
#t27_62{left:642px;bottom:652px;}
#t28_62{left:655px;bottom:652px;letter-spacing:-0.09px;}
#t29_62{left:655px;bottom:633px;letter-spacing:-0.12px;}
#t2a_62{left:705px;bottom:640px;}
#t2b_62{left:620px;bottom:614px;}
#t2c_62{left:636px;bottom:614px;letter-spacing:-0.09px;}
#t2d_62{left:642px;bottom:595px;}
#t2e_62{left:655px;bottom:595px;letter-spacing:-0.09px;}
#t2f_62{left:1125px;bottom:602px;letter-spacing:-0.12px;}
#t2g_62{left:614px;bottom:392px;letter-spacing:-0.09px;}
#t2h_62{left:614px;bottom:373px;letter-spacing:-0.09px;}
#t2i_62{left:614px;bottom:353px;letter-spacing:-0.08px;}
#t2j_62{left:627px;bottom:249px;}
#t2k_62{left:637px;bottom:243px;letter-spacing:0.11px;}
#t2l_62{left:636px;bottom:226px;letter-spacing:0.08px;word-spacing:0.04px;}
#t2m_62{left:636px;bottom:209px;letter-spacing:0.12px;}
#t2n_62{left:627px;bottom:198px;}
#t2o_62{left:637px;bottom:192px;letter-spacing:0.12px;word-spacing:-0.03px;}
#t2p_62{left:1147px;bottom:192px;}
#t2q_62{left:627px;bottom:182px;}
#t2r_62{left:637px;bottom:176px;letter-spacing:-0.03px;}
#t2s_62{left:636px;bottom:159px;letter-spacing:-0.04px;}
#t2t_62{left:636px;bottom:142px;letter-spacing:-0.04px;}
#t2u_62{left:636px;bottom:125px;letter-spacing:-0.04px;}
#t2v_62{left:636px;bottom:108px;letter-spacing:-0.03px;}
#t2w_62{left:744px;bottom:108px;letter-spacing:-0.02px;}
#t2x_62{left:816px;bottom:108px;letter-spacing:-0.07px;}
#t2y_62{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_62{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_62{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_62{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_62{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_62{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_62{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_62{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_62{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_62{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_62{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_62{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_62{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_62{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_62{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_62{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts62" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg62Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg62" style="-webkit-user-select: none;"><object width="1210" height="935" data="62/62.svg" type="image/svg+xml" id="pdf62" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_62" class="t s0_62">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_62" class="t s1_62">® </span>
<span id="t3_62" class="t s0_62">(NCCN </span>
<span id="t4_62" class="t s1_62">® </span>
<span id="t5_62" class="t s0_62">), All rights reserved. NCCN Guidelines </span>
<span id="t6_62" class="t s1_62">® </span>
<span id="t7_62" class="t s0_62">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_62" class="t s2_62">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_62" class="t s2_62">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_62" class="t s3_62">NCCN Guidelines Version 4.2024 </span>
<span id="tb_62" class="t s3_62">Ethmoid Sinus Tumors </span>
<span id="tc_62" class="t s4_62">NCCN Guidelines Index </span>
<span id="td_62" class="t s4_62">Table of Contents </span>
<span id="te_62" class="t s4_62">Discussion </span>
<span id="tf_62" class="t s5_62">ETHM-A </span>
<span id="tg_62" class="t s6_62">1 </span>
<span id="th_62" class="t s7_62">See Principles of Radiation Techniques (RAD-A) </span><span id="ti_62" class="t s8_62">and </span><span id="tj_62" class="t s7_62">Discussion</span><span id="tk_62" class="t s8_62">. </span>
<span id="tl_62" class="t s6_62">2 </span>
<span id="tm_62" class="t s8_62">In the paranasal sinus area, care should be taken to avoid critical neural structures; </span>
<span id="tn_62" class="t s8_62">therefore, 1.8 Gy/fraction can be considered. </span>
<span id="to_62" class="t s6_62">3 </span>
<span id="tp_62" class="t s8_62">For doses &gt;70 Gy, some clinicians feel that the fractionation should be slightly </span>
<span id="tq_62" class="t s9_62">modified (eg, &lt;2.0 Gy/fraction for at least some of the treatment) to minimize </span>
<span id="tr_62" class="t s8_62">toxicity. An additional 2–3 doses can be added depending on clinical circumstances. </span>
<span id="ts_62" class="t s6_62">4 </span>
<span id="tt_62" class="t s8_62">Suggest 44–50 Gy in sequentially planned IMRT or 54–63 Gy with IMRT dose </span>
<span id="tu_62" class="t s8_62">painting technique (dependent on dose per fraction). </span>
<span id="tv_62" class="t s5_62">PRINCIPLES OF RADIATION THERAPY </span>
<span id="tw_62" class="t sa_62">1 </span>
<span id="tx_62" class="t s5_62">DEFINITIVE: </span>
<span id="ty_62" class="t s5_62">RT Alone </span>
<span id="tz_62" class="t s5_62">• PTV </span>
<span id="t10_62" class="t sb_62"></span><span id="t11_62" class="t s5_62">High risk: Primary tumor and involved lymph nodes [this includes </span>
<span id="t12_62" class="t sc_62" data-mappings='[[29,"fi"]]'>possible local subclinical inﬁltration at the primary site and at the </span>
<span id="t13_62" class="t s5_62">high-risk level lymph node(s)] </span>
<span id="t14_62" class="t sd_62">◊ </span><span id="t15_62" class="t s5_62">Fractionation: </span>
<span id="t16_62" class="t s5_62">– 66 Gy (2.2 Gy/fraction) to 70–70.2 Gy (1.8–2.0 Gy/fraction); </span>
<span id="t17_62" class="t s5_62">daily Monday–Friday in 6–8 weeks </span>
<span id="t18_62" class="t sa_62">2,3 </span>
<span id="t19_62" class="t s5_62">– Concomitant boost accelerated RT: </span>
<span id="t1a_62" class="t sc_62">▪ </span><span id="t1b_62" class="t s5_62">72 Gy/6 weeks (2 Gy once daily and then 1.8 Gy/fraction, </span>
<span id="t1c_62" class="t sc_62" data-mappings='[[6,"fi"]]'>large ﬁeld; 1.5 Gy boost as second daily fraction during last </span>
<span id="t1d_62" class="t s5_62">12 treatment days) </span>
<span id="t1e_62" class="t sc_62">▪ </span><span id="t1f_62" class="t s5_62">66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </span>
<span id="t1g_62" class="t s5_62">– Hyperfractionation: 81.6 Gy/7 weeks (1.2 Gy/fraction, twice </span>
<span id="t1h_62" class="t s5_62">daily) </span>
<span id="t1i_62" class="t sb_62"></span><span id="t1j_62" class="t s5_62">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1k_62" class="t sd_62">◊ </span><span id="t1l_62" class="t s5_62">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1m_62" class="t sa_62">4,5 </span>
<span id="t1n_62" class="t s5_62">CONCURRENT SYSTEMIC THERAPY/RT: </span>
<span id="t1o_62" class="t sa_62">6 </span>
<span id="t1p_62" class="t s5_62">• PTV </span>
<span id="t1q_62" class="t sb_62"></span><span id="t1r_62" class="t s5_62">High risk: Typically 70–70.2 Gy (1.8–2.0 Gy/fraction); daily Monday– </span>
<span id="t1s_62" class="t s5_62">Friday in 7–8 weeks </span>
<span id="t1t_62" class="t sa_62">2 </span>
<span id="t1u_62" class="t sb_62"></span><span id="t1v_62" class="t s5_62">Low to intermediate risk: 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy </span>
<span id="t1w_62" class="t s5_62">(1.6–1.8 Gy/fraction) </span>
<span id="t1x_62" class="t sa_62">4,5 </span>
<span id="t1y_62" class="t s5_62">POSTOPERATIVE: </span>
<span id="t1z_62" class="t s5_62">RT or Concurrent Systemic Therapy/RT </span>
<span id="t20_62" class="t sa_62">6 </span>
<span id="t21_62" class="t s5_62">• </span><span id="t22_62" class="t sc_62">Preferred interval between resection and postoperative RT is ≤6 weeks </span>
<span id="t23_62" class="t s5_62">• PTV </span>
<span id="t24_62" class="t sb_62"></span><span id="t25_62" class="t s5_62">High risk: Adverse pathologic features such as positive margins </span>
<span id="t26_62" class="t sa_62">7 </span>
<span id="t27_62" class="t sd_62">◊ </span><span id="t28_62" class="t s5_62">60–66 Gy (1.8–2.0 Gy/fraction); daily Monday–Friday in 6–6.5 </span>
<span id="t29_62" class="t s5_62">weeks </span>
<span id="t2a_62" class="t sa_62">2 </span>
<span id="t2b_62" class="t sb_62"></span><span id="t2c_62" class="t s5_62">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t2d_62" class="t sd_62">◊ </span><span id="t2e_62" class="t s5_62">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t2f_62" class="t sa_62">4,5 </span>
<span id="t2g_62" class="t s5_62">Either IMRT or proton therapy is recommended for maxillary sinus </span>
<span id="t2h_62" class="t s5_62">or paranasal/ethmoid sinus tumors to minimize dose to critical </span>
<span id="t2i_62" class="t s5_62">structures. </span>
<span id="t2j_62" class="t s6_62">5 </span>
<span id="t2k_62" class="t s8_62">Treatment to sites of suspected subclinical spread is not consistently performed </span>
<span id="t2l_62" class="t s8_62">at all institutions. (Le QT, Fu KK, Kaplan MJ, et al. Lymph node metastasis in </span>
<span id="t2m_62" class="t s8_62">maxillary sinus carcinoma. Int J Radiat Oncol Biol Phys 2000;46:541-549.) </span>
<span id="t2n_62" class="t s6_62">6 </span>
<span id="t2o_62" class="t s7_62">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="t2p_62" class="t s8_62">. </span>
<span id="t2q_62" class="t s6_62">7 </span>
<span id="t2r_62" class="t s8_62">Adverse pathologic features: positive margins, close margins (tumors adjacent to </span>
<span id="t2s_62" class="t s8_62">the cribriform plate and/or medial wall of the orbit), unfavorable histology (ie, high </span>
<span id="t2t_62" class="t s8_62">grade, adenoid cystic), intracranial and/or intraorbital extension, cribriform plate </span>
<span id="t2u_62" class="t s8_62">location, medial wall of orbit location, perineural invasion, and lymphovascular </span>
<span id="t2v_62" class="t s8_62">space invasion (</span><span id="t2w_62" class="t s7_62">Discussion</span><span id="t2x_62" class="t s8_62">). </span>
<span id="t2y_62" class="t se_62">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
